Introduction
Staphylococcus aureus is a notorious human pathogen that causes a wide range of clinical infections. It is a major cause of bloodstream infections and infective endocarditis as well as osteoarticular, skin and soft tissue, pleuropulmonary, and implant-associated infections [1]. Although S. aureus accounts for only 0.5-6% of urinary tract infections (UTIs), untreated infection can lead to severe life-threatening conditions [2]. Isolation of S. aureus from urine samples must be investigated further to rule out staphylococcal bacteremia arising from elsewhere (e.g., in cases of endocarditis). Nonetheless, in certain patients, S. aureus causes ascending urinary tract colonization and infection. This usually occurs in patients with urinary tract instrumentation and/or the presence of an indwelling catheter [3,4]. Although the majority of S. aureus bacteriuria cases are asymptomatic, when symptoms appear, the most common symptom of S. aureus UTI is fever. Other symptoms include hematuria, altered mental status, dysuria, suprapubic pain, and, less commonly, flank pain [5]. Methicillin-resistant S. aureus (MRSA) UTI is associated with recent antibiotic use and urinary catheterization and leads to longer stays in healthcare facilities. The strong association of catheters with UTI signifies the importance of reducing the use of urinary catheterization to essential cases only and removal of the device as soon as clinically indicated. Patients with catheter-associated S. aureus UTI, after excluding bacteremia, should be treated for 10 to 14 days with appropriate antimicrobials, as determined by culture and susceptibility results, as well as removal or replacement of the catheter [1].
Several studies reported S. aureus UTI in skilled-care nursing homes, long-term care facilities, and attending specialist and tertiary hospitals [3,4,6,7]. The aim of this study was to assess the clinical presentation, risk factors, and comorbidities of the patients with S. aureus bacteriuria, and to analyze antimicrobial susceptibility data of S. aureus isolates from urine samples in a community-based healthcare center.
Materials and methods
Study population and sample collection
A retrospective observational cohort study was conducted at Dr. Sulaiman Al-Habib Hospital (HMG), Takhassusi branch in Riyadh, Saudi Arabia, and approved by the Institutional Review Board (IRB) of HMG (approval number: RC20.12.117). A total of 85 patients with S. aureus bacteriuria (positive urine culture for S. aureus) were enrolled in this study from the first of January, 2017 to the end of June, 2020. The initial S. aureus isolated from urine culture was included for all the study subjects. If the subsequent S. aureus from urine culture for the same patient showed identical susceptibility results, they were considered as a single isolate, and the second one was excluded. However, if the second isolate had a different susceptibility result, it was considered a different strain and included in the total number of S. aureus isolates (n = 90). Four patients had more than one isolate with different susceptibility results, and all were included. Registries containing patients' demographics and clinical and laboratory data were extracted from the VIDA system (HMG hospital information system).
Urinalysis
Urinalysis was performed manually, including the macroscopic examination (color and appearance) and microscopic examination for the presence of urinary WBCs, RBCs, and bacteria. A chemistry analyzer (CLINITEK Advantus, Siemens Healthineers, Erlangen, Germany) was used to measure nitrates and leukocyte esterase.
Urine culture
The culture results were interpreted based on the colony count, the number of organisms, and the presence of symptoms [8]. Full identification and susceptibility testing of S. aureus were performed by the VITEK 2 system (BioMérieux, Marcy-l'Étoile, France) using the manufacturer’s recommendations. The VITEK system was used to detect MRSA by cefoxitin screening and performing oxacillin minimum inhibitory concentration.
Statistical analysis
Frequency and percentages were used for descriptive analysis, and cross-tabulation was used to identify the relationship between categorical variables. Using the chi-square test, a p-value of 0.05 or less was considered significant. All data analysis was performed with SPSS version 26 (IBM Corp., Armonk, NY).
Results
From January 2017 to June 2020, we identified and included 85 consecutive patients in the study. A total of 81 S. aureus were isolated from 81 patients, while three S. aureus were isolated from one patient, and two S. aureus were isolated from each of the three patients. The majority of the patients were female (62%) and the ages ranged from less than one month to 83 years with a mean age of 32.9 years. Most of the patients (85%) were outpatients. Of the patients, 47 were previously healthy with no underlying disease while 14, 13, 11, and six had a past history of recurrent UTI, diabetes, hypertension, and a Foley catheter of some type in place, respectively. Some patients had structural and or functional urinary tract dysfunctions such as renal stones, vesicoureteral reflux, and renal cysts. Seventy positive urine cultures were associated with UTI symptoms, while 16 cultures were associated with non-specific symptoms or symptoms not related to UTI, and four cultures were from asymptomatic individuals. The most common presentation was dysuria (40%), associated with other UTI symptoms such as hematuria, suprapubic pain, and frequency. Table 1 presents the patients’ characteristics and underlying medical conditions and symptoms at the time of positive urine culture for S. aureus.
Table 1
Characteristics of 85 patients and symptoms at the time of positive urine culture for Staphylococcus aureus.
Characteristics | Value |
Mean age (years) | 32.9 |
Median age (years) | 28 |
Gender (percentage) | |
Male | 32 (38) |
Female | 53 (62) |
Patient location at the time of ordering the urine culture (percentage) | |
Inpatient | 13 (15) |
Outpatient | 72 (85) |
Underlying condition with the number of patients (percentage) | |
Previously healthy | 47 (52) |
Diabetes | 13 (15) |
Hypertension | 11 (13) |
Foley’s catheter | 6 (7) |
Recurrent urinary tract infection | 14 (17) |
Renal stones | 5 (6) |
Vesicoureteral reflux | 2 (2) |
Renal cysts | 2 (2) |
Multiple bladder diverticulum | 1 (1) |
Neurogenic bladder | 5 (6) |
Benign prostatic hyperplasia | 2 (2) |
Single kidney | 2 (2) |
Symptoms (percentage) | |
Fever | 17 (19) |
Hematuria | 12 (13) |
Suprapubic pain | 16 (18) |
Dysuria | 36 (40) |
Flank pain | 22 (24) |
Frequency | 7 (8) |
Urgency | 5 (6) |
Urine retention | 2 (2) |
Asymptomatic bacteriuria | 4 (4) |
The study included 77 patients for whom urinalysis was performed, of which 58 were positive for UTI. In Table 2, details about the frequency of positivity of the individual components of the urinalysis are provided. Twelve urinalyses were positive for nitrite, while 58 of them were positive for WBCs, 56 were positive for bacteria, and 38 were positive for RBCs.
Table 2
Urinalysis for 77 patients.
Result | No. of tests |
Positive for nitrite | 12 |
Positive for WBCs | 58 |
Positive for RBCs | 38 |
Positive for bacteria | 56 |
During the study period, we received 44,884 urine samples for culture and susceptibility testing. Among these urine cultures, 8322 (19%) were positive for uropathogens. S. aureus accounted for 1.08% of other uropathogens as presented in Figure 1.
Figure 1
Percentage of S. aureus urinary tract infections among other uropathogens.
Table 3 presents the susceptibility results of all 90 S. aureus isolates. Twenty-two (24%) of these were MRSA. All of these were susceptible to vancomycin, teicoplanin, and linezolid, and 91% were susceptible to trimethoprim/sulfamethoxazole.
Table 3
Number of susceptible isolates (%).
Antibiotic | No. of susceptible isolates (%) |
Penicillin | 12 (13%) |
Oxacillin | 68 (76%) |
Erythromycin | 77 (86%) |
Clindamycin | 84 (93%) |
Gentamicin | 87 (97%) |
Trimethoprim-sulfamethoxazole | 82 (91%) |
Fusidic acid | 61 (68%) |
Tetracycline | 78 (87%) |
Vancomycin | 90 (100%) |
Teicoplanin | 90 (100%) |
Linezolid | 90 (100%) |
The antimicrobial resistance rate in MRSA isolates was much higher than methicillin-sensitive S. aureus (MSSA) UTI isolates, with P < 0.05, except for gentamicin and tetracycline. Table 4 shows the susceptibility results of MRSA and MSSA isolates.
Table 4
MSSA versus MRSA resistance rates (%) of the tested antibiotics.
MSSA: methicillin-sensitive Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus.
MSSA | MRSA | P-value | |
Penicillin | 56 (82) | 22 (100) | 0.034 |
Erythromycin | 6 (9) | 7 (32) | 0.008 |
Clindamycin | 2 (3) | 4 (18) | 0.013 |
Gentamicin | 1 (1.5) | 2 (9) | 0.083 |
Trimethoprim-sulfamethoxazole (%) | 1 (1.5) | 7 (32) | 0.000 |
Fusidic acid | 14 (21) | 12 (55) | 0.008 |
Tetracycline | 7 (10) | 5 (23) | 0.136 |
The MRSA-associated UTIs were significantly more prevalent in patients with underlying medical problems (P = 0.007).
While comparing outpatients with inpatients, we found that inpatients had higher percentages of elderly (38.5%), male (61.5%), and patients with underlying medical conditions and/or urinary structural abnormalities (53.8%). However, it was statistically insignificant with P > 0.05. See Table 5 for further details.
Table 5
Patients’ characteristics in relation to outpatient and inpatient settings.
Outpatient | Inpatient | P-value | |
Age group | 0.354 | ||
0-15 years | 20 (27.8%) | 4 (30.8%) | |
15-45 years | 36 (50%) | 4 (30.8%) | |
>45 years | 16 (22.2%) | 5 (38.5%) | |
Gender | 0.053 | ||
Male | 24 (33.3%) | 8 (61.5%) | |
Female | 48 (66.7%) | 5 (38.5%) | |
Underlying conditions | 0.531 | ||
Previously healthy | 40 (55.6%) | 6 (46.2%) | |
Patients with underlying medical conditions and/or urinary structural abnormalities | 32 (44.4%) | 7 (53.8%) |
Discussion
S. aureus is not a frequent UTI pathogen in the general population. Correspondingly, in the present study, the prevalence rate of S. aureus bacteriuria accounted for only 1% of all urine isolates. Comparably, Goldstein conducted a laboratory-based study in France and found that S. aureus accounted for only 1.3% of isolates from urine specimens submitted from the community [9]. Similarly, in a multicenter community-based study conducted by Barrett et al. in Great Britain, S. aureus comprised only 0.5% of all UTI isolates [10].
It has been previously described that isolation of S. aureus from the urine is almost invariably associated with urine catheterization, or dissemination through a hematogenous route, affecting mainly elderly patients [4]. This fact is also supported by the research of Muder et al., who conducted a longitudinal study of 102 patients at a long-term veteran care facility with documented S. aureus bacteriuria and found that 13% of the patients with S. aureus isolated from their urine were bacteremic and 53% had bladder catheters [5]. The most common symptom associated with S. aureus UTI was fever. Other symptoms were hematuria, altered mental status, dysuria, suprapubic pain, and, less commonly, flank pain [5]. However, in our study, the picture was significantly different. The majority of the patients were female aged from 15 to 45 years. Interestingly, underlying medical conditions, urinary tract manipulations, or abnormalities were uncommon. Only 7% of the patients had indwelling urinary catheters. Blood cultures were not performed for most of the patients, possibly because the majority of the patients presented to the clinics with simple cystitis, and urosepsis was not initially suspected. The most common presentation was dysuria, which may represent simple cystitis rather than pyelonephritis. The possible explanation is our hospital setting where the majority of patients visit the emergency department and a variety of different specialty clinics. As many as 85% of the study subjects were outpatients. Therefore, our study mainly represented community-acquired infections.
A number of studies have indicated that the majority of S. aureus bacteriuria cases are not associated with symptoms of UTI and merely represent colonization. For example, Muder et al. found that only 33% of the patients with S. aureus isolated from their urine had UTI symptoms [5]. Likewise, in another retrospective cohort study, Capitano et al. identified 90 S. aureus infections in a single nursing home. Of these, 48% were classified as UTI using a definition of fever (temperature > 37.5°C) in association with staphylococcal bacteriuria, while 52% of the isolates were considered as just colonizers [6]. Furthermore, Pacio et al. reported that only 13% of long-term care patients colonized with MRSA at any site developed symptomatic UTIs [11]. In contrast, because of the different study population, 81.1% of the patients in the present study had UTI symptoms, and/or positive urinalysis for UTI, which represents true infection rather than colonization. Urinalysis is one of the most important tests to diagnose UTI and differentiate between colonization and true infection. However, it was not performed for eight patients in the present study, possibly due to typical symptoms of UTI, and only culture results were requested to determine the type of pathogen and susceptibility test results. The UTIs caused by MRSA are associated with longer stays in healthcare facilities, recent antibiotic use, and urinary catheterization [3,5]. In our study, out of 24 patients infected with MRSA, 16 patients had underlying medical conditions.
Several studies have reported different susceptibility patterns of S. aureus to a variety of tested antibiotics. This could be due to the selection criteria for S. aureus isolates and the study population. In a study of S. aureus biofilm formation in UTI, Yousefi et al. found that out of 39 S. aureus isolates, 30 isolates were MRSA. The overall susceptibility of S. aureus isolates to antimicrobial agents was 100% for linezolid and quinupristin/dalfopristin, 97.4% for chloramphenicol, 76.9% for trimethoprim-sulfamethoxazole, 64.1% for rifampin, 43.6% for clindamycin, 41% for nitrofurantoin, doxycycline, and gentamicin, 35.9% for erythromycin and ciprofloxacin, and 33.3% for tetracycline; however, vancomycin susceptibility was not reported in this study [2]. Yousefi et al. published another study about tigecycline- and vancomycin-resistant S. aureus strains among patients with UTI. The results revealed that the MRSA isolates were 100% susceptible to linezolid and quinupristin/dalfopristin but 93.3% were susceptible to vancomycin and tigecycline [12]. Antibiogram of S. aureus isolated from urine samples of patients with suspected cases of UTI performed by Akortha et al. showed the following results: the sensitivity pattern of S. aureus is 83%, 79.9%, 63.5%, 58.9%, and 50.2% to amoxicillin-clavulanic acid, ofloxacin, nitrofurantoin, amoxicillin, and gentamicin, respectively, while S. aureus isolates are 87.3%, 80.9%, and 79.3% resistant to trimethoprim-sulfamethoxazole, tetracycline, and nalidixic acid, respectively, but nothing is mentioned about vancomycin [13]. In our study, 24% of the isolates were MRSA. The antimicrobial susceptibility rate was much higher than the previously mentioned studies, which represents the susceptibility pattern of S. aureus causing UTI in the community. According to our results, 91% of S. aureus isolated from urine were susceptible to trimethoprim-sulfamethoxazole, which can be used as empiric treatment if S. aureus is suspected to be the cause of UTI or reported as a preliminary result before susceptibility results are available. Isolation of S. aureus from urine in patients without an obvious cause may indicate S. aureus bacteremia, therefore, it is necessary to perform blood cultures for any patient with positive S. aureus urine culture. As noted in the result section, resistance rates of the antibiotics in MRSA are much higher than MSSA UTIs, with a P-value < 0.05 for most of the antibiotics. This is understandable as some MRSA strains contain a plasmid that carries resistance genes for beta-lactams, fluoroquinolones, tetracycline, macrolides, clindamycin, and mupirocin [14].
Conclusions
Although S. aureus UTI is known to be associated with other risk factors such as urinary catheterization, long hospital stay, or complicated UTI, our results show the community-acquired presentation of UTI. Trimethoprim-sulfamethoxazole may be used as an effective treatment for UTI caused by S. aureus. S. aureus UTI could be an alarming sign of more invasive infections such as S. aureus bacteremia, though clinical evaluation and finding the source of S. aureus are crucial for effective treatment and prevention of further complications.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright © 2023, Alshomrani et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Background
The aim of this study was to assess the clinical presentation, risk factors, and comorbidities of the patients with Staphylococcus aureus bacteriuria, and to analyze the antimicrobial susceptibility data of S. aureus isolated from their urine samples.
Methods
A total of 90 isolates of S. aureus were collected from patients with urinary tract infections (UTIs). Urinalysis was performed manually, including macroscopic examination of color and appearance, and microscopic examination for the presence of urinary WBCs, RBCs, and bacteria. Full identification and susceptibility testing of S. aureus were performed by the VITEK 2 system (BioMérieux, Marcy-l'Étoile, France) using standard criteria.
Results
The majority of the patients were female (62%), with a mean age of 32.9 years. Most of the patients were outpatients (85%), and 52% were previously healthy with no underlying disease. Seventy positive urine cultures were associated with UTI symptoms, and the most common symptom was dysuria (40%). Out of 77 urinalyses performed, 58 were positive for UTI. Of the S. aureus isolated, 24% were methicillin-resistant S. aureus (MRSA). Susceptibility to vancomycin, teicoplanin, and linezolid was 100%, while susceptibility to erythromycin, clindamycin, gentamicin, trimethoprim-sulfamethoxazole, fusidic acid, and tetracycline, was 86%, 93%, 97%, 91%, 68%, and 87%, respectively.
Conclusion
Although S. aureus UTI is known to be associated with other risk factors such as urinary catheterization, long hospital stay, or complicated UTI, our results show the community-acquired presentation of UTI. Trimethoprim-sulfamethoxazole may be used as an effective treatment for UTI caused by S. aureus. S. aureus UTI could be an alarming sign of more invasive infections such as S. aureus bacteremia, though clinical evaluation and finding the source of S. aureus are crucial for effective treatment and prevention of further complications.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer